Second-line therapy for ovarian cancer.
Markman
Maurie
M
The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D050257:Tubulin Modulators / Q000008:administration & dosage / Q000009:adverse effects
D000903:Antibiotics, Antineoplastic; D050257:Tubulin Modulators; D016190:Carboplatin